Eisenberg et al. first demonstrated that adding soluble SLAMF6 augmented anti-melanoma CD8+ T cell effector performance, produced more IFN-γ, and displayed enhanced cytotoxicity in vitro and in vivo [29]. The gene discussed is SLAMF6; the disease is melanoma.